Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
1(17%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
17%
Ph not_applicable
1
17%
Ph phase_1
1
17%
Ph phase_2
3
50%

Phase Distribution

1

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(5)

Detailed Status

Completed5
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 23 (50.0%)
Phase 31 (16.7%)
N/A1 (16.7%)

Trials by Status

recruiting117%
completed583%

Recent Activity

1 active trials
Showing 5 of 6
recruitingphase_3

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

NCT06790784
completednot_applicable

Evaluation of Macular Structural and Functional Function Following Extensive Retinal Laser Therapy in Patients With Proliferative Diabetic Retinopathy

NCT04436900
completedphase_2

Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.

NCT01941329
completedphase_2

Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy

NCT01280929
completedphase_2

Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.

NCT01281098
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06790784Phase 3

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

Recruiting
NCT04436900Not Applicable

Evaluation of Macular Structural and Functional Function Following Extensive Retinal Laser Therapy in Patients With Proliferative Diabetic Retinopathy

Completed
NCT01941329Phase 2

Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.

Completed
NCT01280929Phase 2

Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy

Completed
NCT01281098Phase 2

Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.

Completed
NCT00295828Phase 1

A Pilot Study for the Treatment of Iris Neovascularization With Macugen

Completed

All 6 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
6